DB01061ApprovedSmall molecule
Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.
- Mechanism
- Curator reviewed
By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, azlocillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that azlocillin interferes with an autolysin inhibitor.
- Primary indication
- For the treatment of infections caused by Pseudomonas aeruginosa, Escherichia coli, and Haemophilus influenzae.Curator reviewed
- Formula / weight
- C20H23N5O6S · 461.492 g/mol (avg)
Resolves to
Clinical / RWD
Structure
InChIKey
JTWOMNBEOCYFNV-NFFDBFGFSA-NSMILES[H][C@](NC(=O)N1CCNC1=O)(C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])C1=CC=CC=C1Targets
What you can answer from here — as of September 16, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Azlocillin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account